Article
Analytical Methods for Cell Therapy — Validating Flow Cytometry, Potency, and Release Assays
The analytical methods used to characterize and release cell therapy products are unlike any other in pharmaceutical science. Validating them to ICH Q2(R2) requires a cell-therapy-specific strategy that…
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
Analytical Methods for Cell Therapy — Validating Flow Cytometry, Potency, and Release Assays
The analytical methods used to characterize and release cell therapy products are unlike any other in pharmaceutical science. Validating them to ICH Q2(R2) requires a cell-therapy-specific strategy that…
Article
Process Validation for Cell Therapy — FDA Three-Stage Framework for a Living Drug
Process validation for cell therapy is not impossible — it is just different. The FDA's 2011 guidance applies. But the way you design Stage 1, execute Stage 2,…
Article
Cell Therapy Stability — Designing a Program for a Drug That Degrades Biologically
Cell therapy stability studies are not shorter versions of biologics stability programs. They are fundamentally different studies — because cell therapy products degrade through biological processes that conventional…
Article
TIL and NK Cell Therapy CMC — Complexity at the Least-Standardized CMC Frontier
Tumor-infiltrating lymphocyte and NK cell therapies occupy the frontier of cell therapy CMC. The regulatory expectations are evolving — but CBER's fundamental requirements for potency, identity, and manufacturing…
Article
iPSC-Derived Cell Therapy CMC — Genomic Integrity, Differentiation Fidelity, Reproducibility
iPSC-derived cell therapies represent the most ambitious manufacturing challenge in modern medicine. The CMC package required to support a CBER IND for one of these products reflects that…
Article
Allogeneic Cell Therapy CMC — The Batch Manufacturing Model That Changes Module 3
Allogeneic cell therapy does what autologous cannot: it makes a single manufacturing batch that can treat hundreds of patients. The CMC infrastructure required to support that model is…
Article
Cryopreservation, Storage, and Shipping — The Cold Chain CMC Evidence Package
The most technically sophisticated cell therapy can be destroyed between the manufacturing facility and the clinic. Cold chain failures in cell therapy are CMC failures — and CBER…
Article
Chain of Identity and Chain of Custody — The CMC System That Cannot Fail
In autologous cell therapy, chain-of-identity failure is not a quality event — it is a patient safety catastrophe. The CMC section that describes your CoI system is evaluated…
Article
Cell Therapy Lot Release Specifications — Acceptance Criteria That Protect Patients and Enable Manufacturing
The specifications for a cell therapy lot are the single document that determines what goes into a patient. In personalized medicine manufacturing, they also determine whether you can…
Article
Cell Therapy Potency — The Most Consequential and Difficult CMC Problem in Your Program
Potency for a cell therapy product is not a release test. It is the primary regulatory evidence that manufacturing produced cells that can do what the label claims.…
Article
CAR-T Manufacturing — The Process Description That CBER Needs to Understand Your Drug
A CAR-T manufacturing process description is the only place in a CMC package where a reviewer can see whether you understand that every step modifies the drug. Most…
Article
Starting Material Control — Apheresis, Donor Qualification, and the CMC Sections CBER Scrutinizes
The most consequential CMC decision in an autologous cell therapy program is not the manufacturing process — it is how you define, characterize, and control the starting material…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.